HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.
about
Analysis of longitudinal multivariate outcome data from couples cohort studies: application to HPV transmission dynamics.A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionGlutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirusComparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected WomenDevelopment and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine typesNatural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.Clinical trials of human papillomavirus vaccines and beyond.Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution.Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era.
P2860
Q30981780-D9F368E0-88C7-4814-9E7A-36A0C06173C0Q34970731-ADA75E7F-AB90-4B94-811D-41E295F2CCE1Q35109451-DAE8A06F-1B9F-4065-981E-FED6C391D017Q35743769-0FBF41E5-A20F-415B-9718-767E84B18478Q36104074-B7255E2D-123F-40C5-8524-46DF26CFC718Q36745242-F22CEAF4-F2BE-4385-A48C-FEA1BD7BA6B9Q36974917-3915B160-38D3-45EE-A4A1-4ECB9366B2D2Q37162220-6E175A69-C523-4786-A8F8-02572E656160Q37466826-561FC1E6-7626-45AA-AB02-BEC735636B6FQ38111962-CD885A5B-50C5-47AC-B1DF-CA3BA31727C1Q40571982-49597269-2B57-4705-9340-4148C6A55B1EQ40721764-52A1D7BC-93B8-478E-A738-1B0E5175423CQ41933591-E3631E6D-CB12-42CA-B107-138906DAD636Q51103584-65ED8139-9237-467F-998D-4C67BDE76710
P2860
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HPV16 seropositivity and subse ...... parison of serological assays.
@ast
HPV16 seropositivity and subse ...... parison of serological assays.
@en
HPV16 seropositivity and subse ...... parison of serological assays.
@nl
type
label
HPV16 seropositivity and subse ...... parison of serological assays.
@ast
HPV16 seropositivity and subse ...... parison of serological assays.
@en
HPV16 seropositivity and subse ...... parison of serological assays.
@nl
prefLabel
HPV16 seropositivity and subse ...... parison of serological assays.
@ast
HPV16 seropositivity and subse ...... parison of serological assays.
@en
HPV16 seropositivity and subse ...... parison of serological assays.
@nl
P2093
P2860
P50
P1433
P1476
HPV16 seropositivity and subse ...... parison of serological assays.
@en
P2093
Ariane Meuree
Carolina Porras
Costa Rican Vaccine Trial Group
Katie Matys
Ligia A Pinto
Mark T Esser
Paula Gonzalez
Rolando Herrero
Sarah C Markt
Shih-Wen Lin
P2860
P304
P356
10.1371/JOURNAL.PONE.0053067
P407
P50
P577
2013-01-02T00:00:00Z